SEC Form SC 13G/A filed by Vanda Pharmaceuticals Inc. (Amendment)
$VNDA
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/31/2024 | $18.00 | Buy | H.C. Wainwright |
7/11/2024 | $11.00 | Overweight | Cantor Fitzgerald |
2/25/2022 | $24.00 → $12.00 | Buy → Hold | Jefferies |
Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling
Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling
Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy